# Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)

> **NCT02494206** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Breast Cancer
- Upper Extremity Lymphedema

## Interventions

- **DRUG:** QBX258

## Key facts

- **NCT ID:** NCT02494206
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02494206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02494206, "Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02494206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*